Inhibition of noradrenergic and corticotrophin-releasing factor systems: Effects on enhancement of memory consolidation by unconditioned and conditioned heroin withdrawal.


Journal

Neuropharmacology
ISSN: 1873-7064
Titre abrégé: Neuropharmacology
Pays: England
ID NLM: 0236217

Informations de publication

Date de publication:
15 05 2022
Historique:
received: 26 10 2021
revised: 21 02 2022
accepted: 24 02 2022
pubmed: 4 3 2022
medline: 15 4 2022
entrez: 3 3 2022
Statut: ppublish

Résumé

The aim of the current study was to test the hypothesis that unconditioned and conditioned opioid withdrawal enhance memory consolidation through overlapping neural systems. The reported experiments focussed on noradrenaline (NA) and corticotrophin-releasing factor (CRF) because of their known involvement in both opioid withdrawal and memory consolidation. Male Sprague-Dawley rats were implanted with subcutaneous osmotic mini-pumps releasing 3.5 mg/kg/day heroin and received injections of 3 mg/kg naloxone (NLX) to precipitate withdrawal. NLX was preceded by 0.1-0.6 mg/kg lofexidine (LOF) (alpha-2 adrenergic agonist) or 10-20 mg/kg antalarmin (ANT) (CRF1 receptor antagonist), and all injections were administered immediately after (i.e., post-training method) the sample phase of the spontaneous object recognition memory task. The same procedure was repeated 7 days after removal of the mini-pumps. To establish conditioned withdrawal, heroin-exposed rats were confined for 2 h in a context (CS+) following injections of 3 mg/kg NLX and in another context (CS-) following vehicle injections. Seven days after removal of mini-pumps, the effects of immediate post-sample exposure to the CS+ (and CS-) preceded by 0.6 mg/kg LOF or 20 mg/kg ANT were assessed. It was found both LOF and ANT blocked the enhancement of object memory by post-sample NLX administration and by exposure to the CS+. These results suggest that pharmacological and psychological withdrawal impact memory storage by activating overlapping NA and CRF systems.

Identifiants

pubmed: 35240132
pii: S0028-3908(22)00077-6
doi: 10.1016/j.neuropharm.2022.109018
pii:
doi:

Substances chimiques

Analgesics, Opioid 0
Narcotics 0
Receptors, Corticotropin-Releasing Hormone 0
Naloxone 36B82AMQ7N
Heroin 70D95007SX
Adrenocorticotropic Hormone 9002-60-2
Corticotropin-Releasing Hormone 9015-71-8
Norepinephrine X4W3ENH1CV

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109018

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Auteurs

Nana Baidoo (N)

Department of Psychology & Collaborative Neuroscience Program, Guelph, Ontario, Canada.

Francesco Leri (F)

Department of Psychology & Collaborative Neuroscience Program, Guelph, Ontario, Canada. Electronic address: fleri@uoguelph.ca.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH